Adverse events60

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

21 to 40 of 60

Type	Event	Organ system	Group	Affected	At risk
other	Application site pain	General disorders	Placebo Treated Arm During the Double Blind Phase	0	106
other	Fatigue	General disorders	All d-ATS Treatment During the Dose-Optimization Phase	10	110
other	Fatigue	General disorders	d-ATS Patch Treated Arm During the Double Blind Phase	1	106
other	Fatigue	General disorders	Placebo Treated Arm During the Double Blind Phase	1	106
other	Application site pruritis	General disorders	All d-ATS Treatment During the Dose-Optimization Phase	9	110
other	Application site pruritis	General disorders	d-ATS Patch Treated Arm During the Double Blind Phase	1	106
other	Application site pruritis	General disorders	Placebo Treated Arm During the Double Blind Phase	1	106
other	Pyrexia	General disorders	All d-ATS Treatment During the Dose-Optimization Phase	7	110
other	Pyrexia	General disorders	d-ATS Patch Treated Arm During the Double Blind Phase	1	106
other	Pyrexia	General disorders	Placebo Treated Arm During the Double Blind Phase	1	106
other	Headache	Nervous system disorders	All d-ATS Treatment During the Dose-Optimization Phase	32	110
other	Headache	Nervous system disorders	d-ATS Patch Treated Arm During the Double Blind Phase	6	106
other	Headache	Nervous system disorders	Placebo Treated Arm During the Double Blind Phase	4	106
other	Dizziness	Nervous system disorders	All d-ATS Treatment During the Dose-Optimization Phase	6	110
other	Dizziness	Nervous system disorders	d-ATS Patch Treated Arm During the Double Blind Phase	1	106
other	Dizziness	Nervous system disorders	Placebo Treated Arm During the Double Blind Phase	2	106
other	Upper respiratory tract infection	Infections and infestations	All d-ATS Treatment During the Dose-Optimization Phase	13	110
other	Upper respiratory tract infection	Infections and infestations	d-ATS Patch Treated Arm During the Double Blind Phase	1	106
other	Upper respiratory tract infection	Infections and infestations	Placebo Treated Arm During the Double Blind Phase	2	106
other	Nasopharyngitis	Infections and infestations	All d-ATS Treatment During the Dose-Optimization Phase	11	110

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01711021/events?page=2

API reference For AI assistants